Cannabis and REM Sleep
What we actually know about how THC, CBD, and cannabis use affect REM sleep, dreaming, and sleep architecture.
Cannabis with THC reliably suppresses REM sleep in the short term — that's one of the better-replicated findings in cannabis sleep research. That's why heavy users often report no dreams, and why people in withdrawal experience vivid 'REM rebound' nightmares. Whether this is good (for PTSD nightmares) or bad (for memory consolidation and long-term sleep health) depends entirely on who you are and how long you use it. Most marketing about cannabis as a 'sleep aid' ignores REM entirely.
Not Medical Advice
This article is not medical advice. It summarizes published research for educational purposes. Sleep disorders, PTSD, and chronic insomnia are serious conditions. If you are considering cannabis for a sleep problem — or trying to stop using it — talk to a clinician familiar with both sleep medicine and cannabis. Drug interactions, withdrawal effects, and underlying conditions all matter.
Plain-language summary
REM (rapid eye movement) sleep is the stage where most vivid dreaming happens. It's important for emotional processing and memory consolidation. Adults normally spend about 20–25% of the night in REM, mostly in the second half of sleep [1].
THC, the main intoxicating compound in cannabis, suppresses REM sleep — meaning you spend less time in it Strong evidence [2][3]. This is why regular cannabis users often say they 'don't dream.' When a chronic user stops, REM bounces back hard, producing intense and sometimes disturbing dreams for one to several weeks. This is called REM rebound Strong evidence [4].
Whether THC's REM suppression is helpful or harmful depends on context. For someone with PTSD nightmares, suppressing REM-linked nightmares may feel like relief. For someone relying on REM for memory consolidation or emotional regulation, chronic suppression is a real cost. CBD's effects on REM are much less clear and probably dose-dependent Weak / limited.
What probably works (stronger evidence)
Acute THC reduces REM sleep. Controlled laboratory studies going back to the 1970s consistently show that THC dosing before bed reduces the percentage of the night spent in REM and increases time in slow-wave (deep) sleep, at least initially Strong evidence [2][3][5].
Stopping cannabis after chronic use causes REM rebound. Polysomnography studies of heavy users in withdrawal show increased REM percentage, shortened REM latency, and vivid dreams or nightmares — peaking in the first week or two and gradually normalizing Strong evidence [4][6]. This is one of the most consistent objective findings in the cannabis withdrawal literature and is part of the DSM-5 criteria for Cannabis Withdrawal Syndrome [7].
Tolerance to sleep effects develops. The subjective 'this knocks me out' effect, and at least some of the objective sleep architecture changes, attenuate with repeated use Strong evidence [3][5]. This is one reason people escalate doses.
What might work (weaker evidence)
Nabilone and synthetic THC for PTSD nightmares. Small open-label studies and one randomized trial of nabilone (a synthetic THC analog) in military and civilian PTSD populations reported reductions in nightmare frequency and severity Weak / limited [8][9]. The mechanism is plausibly REM suppression, but sample sizes are small and long-term outcomes are unclear.
CBD at higher doses may affect sleep architecture. A few studies suggest CBD has dose-dependent effects — possibly alerting at low doses and sedating at higher doses — but data on REM specifically are inconsistent Weak / limited [10]. Most consumer CBD products are dosed far below what was used in those studies.
Cannabis for sleep-disordered breathing. A single small trial (PACE) of dronabinol for obstructive sleep apnea showed modest AHI improvements Weak / limited [11], but the American Academy of Sleep Medicine explicitly does not recommend cannabis or cannabinoids for OSA, citing insufficient evidence and unknown long-term effects [12].
What doesn't work or has weak evidence
'Indica makes you sleepy, sativa is energizing.' Folklore. The indica/sativa distinction does not reliably predict effects on sleep architecture or anything else Disputed [13]. Chemovar (cannabinoid + terpene profile) is a slightly better predictor, but individual variation dominates.
Terpene-specific sleep claims (myrcene, linalool). Frequently marketed, poorly evidenced in humans at the concentrations present in inhaled cannabis Weak / limited.
'Cannabis improves sleep quality overall.' Subjective sleep ratings often improve in the short term, especially for sleep onset, but objective measures (polysomnography) often show worse architecture: less REM, fragmented sleep later in the night, and rebound problems on cessation Disputed [14]. Long-term daily users actually report worse sleep on average than non-users in epidemiological surveys [15].
What we don't know
- Whether chronic REM suppression from long-term cannabis use has measurable consequences for memory consolidation, emotional regulation, or neurodegenerative risk. There are no good long-term polysomnography cohorts.
- Whether REM suppression is the actual mechanism behind any benefit for PTSD nightmares, or whether it's something else (e.g., reduced sympathetic arousal).
- Optimal dosing, timing, and cannabinoid ratios for any sleep indication. Most positive trials are small and short.
- How CBD, CBN ('the sleep cannabinoid' — heavily marketed, very thinly studied Weak / limited), and minor cannabinoids affect REM specifically.
- Whether the REM rebound period carries clinical risks (e.g., for people with trauma histories whose nightmares were being suppressed).
Comparison with standard treatments
For chronic insomnia, first-line treatment is cognitive behavioral therapy for insomnia (CBT-I), which has the strongest evidence base and no REM suppression Strong evidence [16]. Pharmacologic options (e.g., low-dose doxepin, suvorexant, ramelteon) have varying effects on REM; suvorexant and ramelteon are relatively REM-sparing. Benzodiazepines and z-drugs (zolpidem, eszopiclone) suppress REM somewhat but less than THC at typical doses.
For PTSD nightmares, prazosin was long considered first-line; recent trials (PACT, 2018) weakened that picture, and guidelines now treat the evidence as mixed [17]. Image rehearsal therapy has solid evidence. Nabilone is sometimes used off-label where regulations allow [8].
Cannabis is not a recognized first-line treatment for any sleep disorder in major clinical guidelines.
Risks
- Dependence and withdrawal. Daily cannabis use for sleep is a common path into Cannabis Use Disorder. Withdrawal includes insomnia, vivid dreams, irritability, and anxiety — and the sleep symptoms themselves drive relapse Strong evidence [6][7].
- Tolerance. Sleep effects diminish; doses escalate.
- Next-day impairment. Especially with edibles or high-THC products consumed late.
- Worsening of underlying disorders. Untreated sleep apnea, restless legs, and depression-related insomnia can be masked rather than addressed.
- Drug interactions. CBD in particular inhibits CYP450 enzymes and can alter levels of many medications, including some used in sleep and psychiatry Strong evidence [18].
- Pregnancy and adolescence. Cannabis use is not recommended; developing brains are more vulnerable to sleep architecture disruption Strong evidence [19].
See also: Cannabis Use Disorder, Cannabis Withdrawal, CBN, THC.
Sources
- Book Kryger MH, Roth T, Dement WC (eds.). Principles and Practice of Sleep Medicine, 6th ed. Elsevier, 2017.
- Peer-reviewed Pivik RT, Zarcone V, Dement WC, Hollister LE. Delta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns. Clinical Pharmacology & Therapeutics. 1972;13(3):426-435.
- Peer-reviewed Feinberg I, Jones R, Walker JM, Cavness C, March J. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clinical Pharmacology & Therapeutics. 1975;17(4):458-466.
- Peer-reviewed Bolla KI, Lesage SR, Gamaldo CE, et al. Sleep disturbance in heavy marijuana users. Sleep. 2008;31(6):901-908.
- Peer-reviewed Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Current Psychiatry Reports. 2017;19(4):23.
- Peer-reviewed Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry. 2004;161(11):1967-1977.
- Book American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5). 2013.
- Peer-reviewed Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585-588.
- Peer-reviewed Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience & Therapeutics. 2009;15(1):84-88.
- Peer-reviewed Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Journal of Clinical Psychopharmacology. 2004;24(3):305-313.
- Peer-reviewed Carley DW, Prasad B, Reid KJ, et al. Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea. Sleep. 2018;41(1):zsx184.
- Peer-reviewed Ramar K, Rosen IM, Kirsch DB, et al. Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement. Journal of Clinical Sleep Medicine. 2018;14(4):679-681.
- Peer-reviewed Piomelli D, Russo EB. The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research. 2016;1(1):44-46.
- Peer-reviewed Angarita GA, Emadi N, Hodges S, Morgan PT. Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review. Addiction Science & Clinical Practice. 2016;11(1):9.
- Peer-reviewed Conroy DA, Kurth ME, Strong DR, Brower KJ, Stein MD. Marijuana use patterns and sleep among community-based young adults. Journal of Addictive Diseases. 2016;35(2):135-143.
- Peer-reviewed Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine. 2016;165(2):125-133.
- Peer-reviewed Raskind MA, Peskind ER, Chow B, et al. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. New England Journal of Medicine. 2018;378(6):507-517.
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press, 2017. ↗
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Insomnia — What the evidence actually says about using cannabis, THC, CBD, and CBN to fall asleep and...
- Cannabis and PTSD — What the evidence actually says about using cannabis to treat post-traumatic stress disord...
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...